AGEN - Agenus Inc.

-

$undefined

N/A

(N/A)

Agenus Inc. NasdaqCM:AGEN Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Location: 3 Forbes Road, Lexington, MA, 02421-7305, United States | Website: https://www.agenusbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

187M

Cash

18.49M

Avg Qtr Burn

-36.44M

Short % of Float

15.10%

Insider Ownership

1.42%

Institutional Own.

34.05%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Botensilimab (AGEN1181) (anti-CLTA-4) Details
Pancreatic cancer, Melanoma

Big Mover™

Susp. Mover™

Phase 2

Data readout

AGEN1777 (BMS-986442) (TIGIT)+ nivolumab and/or chemotherapies Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s, Lung cancer

Phase 2

Update

Botensilimab (AGEN1181) Details
Cancer, Non-small cell lung carcinoma

Phase 1b

Data readout

AGEN2373 w/ Botensilimab (AGEN1181) Details
Solid tumor/s, Cancer, Melanoma

Phase 1b

Update

Phase 1b

Update

Phase 1b

Update

Phase 1

Update

Failed

Discontinued

Balstilimab (AGEN2034) Details
Cancer, Cervical cancer

Failed

Discontinued

Failed

Discontinued